217 related articles for article (PubMed ID: 18202008)
1. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
Aird KM; Ding X; Baras A; Wei J; Morse MA; Clay T; Lyerly HK; Devi GR
Mol Cancer Ther; 2008 Jan; 7(1):38-47. PubMed ID: 18202008
[TBL] [Abstract][Full Text] [Related]
2. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.
Aird KM; Ghanayem RB; Peplinski S; Lyerly HK; Devi GR
Mol Cancer Ther; 2010 May; 9(5):1432-42. PubMed ID: 20406946
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
[TBL] [Abstract][Full Text] [Related]
4. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
[TBL] [Abstract][Full Text] [Related]
5. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
6. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Huang X; Wang S; Lee CK; Yang X; Liu B
Cancer Lett; 2011 Aug; 307(1):72-79. PubMed ID: 21497990
[TBL] [Abstract][Full Text] [Related]
7. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Xia W; Gerard CM; Liu L; Baudson NM; Ory TL; Spector NL
Oncogene; 2005 Sep; 24(41):6213-21. PubMed ID: 16091755
[TBL] [Abstract][Full Text] [Related]
8. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
[TBL] [Abstract][Full Text] [Related]
9. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.
Allensworth JL; Aird KM; Aldrich AJ; Batinic-Haberle I; Devi GR
Mol Cancer Ther; 2012 Jul; 11(7):1518-27. PubMed ID: 22508521
[TBL] [Abstract][Full Text] [Related]
10. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.
Evans MK; Sauer SJ; Nath S; Robinson TJ; Morse MA; Devi GR
Cell Death Dis; 2016 Jan; 7(1):e2073. PubMed ID: 26821068
[TBL] [Abstract][Full Text] [Related]
11. In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.
Shen G; Huang H; Zhang A; Zhao T; Hu S; Cheng L; Liu J; Xiao W; Ling B; Wu Q; Song L; Wei W
Cancer Immunol Immunother; 2011 Mar; 60(3):339-48. PubMed ID: 21086124
[TBL] [Abstract][Full Text] [Related]
12. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.
Lam PB; Burga LN; Wu BP; Hofstatter EW; Lu KP; Wulf GM
Mol Cancer; 2008 Dec; 7():91. PubMed ID: 19077306
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y; Zi X; Zhao Y; Pollak M
Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
[TBL] [Abstract][Full Text] [Related]
14. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.
Foster FM; Owens TW; Tanianis-Hughes J; Clarke RB; Brennan K; Bundred NJ; Streuli CH
Breast Cancer Res; 2009; 11(3):R41. PubMed ID: 19563669
[TBL] [Abstract][Full Text] [Related]
15. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
16. Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells.
Prabhu KS; Siveen KS; Kuttikrishnan S; Iskandarani A; Tsakou M; Achkar IW; Therachiyil L; Krishnankutty R; Parray A; Kulinski M; Merhi M; Dermime S; Mohammad RM; Uddin S
PLoS One; 2017; 12(7):e0180895. PubMed ID: 28704451
[TBL] [Abstract][Full Text] [Related]
17. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
Lazrek Y; Dubreuil O; Garambois V; Gaborit N; Larbouret C; Le Clorennec C; Thomas G; Leconet W; Jarlier M; Pugnière M; Vié N; Robert B; Monnet C; Bouayadi K; Kharrat H; Mondon P; Pèlegrin A; Chardès T
Neoplasia; 2013 Mar; 15(3):335-47. PubMed ID: 23479511
[TBL] [Abstract][Full Text] [Related]
18. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
19. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
Kim WE; Serrero G
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4192-9. PubMed ID: 16857791
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance.
Dokmanovic M; Shen Y; Bonacci TM; Hirsch DS; Wu WJ
Mol Cancer Ther; 2011 Jun; 10(6):917-28. PubMed ID: 21487052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
